| Literature DB >> 32958079 |
Long Pan1,2,3, Chenhao Tong4, Siyuan Fu5, Jing Fang1,2,3, Qiuxia Gu1,2,3, Shufeng Wang1,2,3, Zhiyu Jiang1,2,3, Sarun Juengpanich1,2,3, Xiujun Cai6,7,8.
Abstract
BACKGROUND: It has been demonstrated that simultaneous resection of both primary colorectal lesion and metastatic hepatic lesion is a safe approach with low mortality and postoperative complication rates. However, there are some controversies over which kind of surgical approach is better. The aim of study was to compare the efficacy and safety of laparoscopic surgeries and open surgeries for simultaneous resection of colorectal cancer (CRC) and synchronous colorectal liver metastasis (SCRLM).Entities:
Keywords: Colorectal cancer; Laparoscopy; Meta-analysis; Synchronous liver metastasis
Mesh:
Year: 2020 PMID: 32958079 PMCID: PMC7507629 DOI: 10.1186/s12957-020-02018-z
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Fig. 1A flow diagram of the inclusion criteria of studies eligible for meta-analysis
Demographics and quality assessments of included studies
| Study, year | Country | Study | Study | Criteria | Matched factorsb | No. of participants (MH, %) | Age, Mean (SD), y | Female, No. (%) | Quality | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inclusion | Exclusiona | ||||||||||||
| Lap | Open | Lap | Open | Lap | Open | ||||||||
| Ma et al. [ | China | 2014–2017 | PSM (R, S) | Primary CRC and SCRLM | 1–3 | 1–3, 5, 7, 11, 12, 15–17, 21, 22,24–26 | 12 (25) | 12 (33) | 3c (25) | 1c (8) | 3 (25) | 4 (33) | 8 |
| Ivanecz et al [ | Slovenia | 2000–2016 | PSM (P, S) | Primary CRC and SCRLM | 4–6 | 1–3, 5, 7, 10–12, 15, 20–27 | 10 (0) | 10 (0) | 62 (8) | 65 (8) | 4 (40) | 4 (40) | 8 |
| Xu et al. [ | China | 2009–2014 | PSM (R, S) | Primary CRC and SCRLM | 5, 7 | 1–3, 5–7, 9, 10, 12, 15–17, 20–22,24– 26, 28 | 20 (25) | 20 (20) | 58 (11) | 60 (11) | 7 (35) | 6 (30) | 8 |
| Chen et al [ | Taiwan, China | 2009–2017 | NM (R, S) | Primary CRC and SCRLM | 2, 6, 8–11 | 1, 2, 7, 11–13, 15, 17, 20, 21, 24, 25, 28, 29 | 16 (19) | 22 (14) | 66 (10) | 65 (13) | 6 (38) | 13 (59) | 6 |
| Gorgun et al [ | USA | 2006–2015 | NM (P, S) | Primary CRC and SCRLM | NR | 1, 2, 3, 7, 9–12, 15, 16, 18, 21, 22,24– 26, 28, 29 | 14 (14) | 29 (14) | 56 (3) | 58 (3) | 8 (57) | 13 (45) | 6 |
| Ratti et al [ | Italy | 2004–2015 | PSM (P, S) | Primary CRC and SCRLM | 4, 12, 13 | 1–3, 5, 10, 12, 16– 18, 20–22, 24–26, 28, 29 | 25 (24) | 50 (20) | 60 (11) | 61 (10) | 11 (44) | 23 (46) | 8 |
| Tranchart et al [ | France | 1997–2013 | PSM (R, M) | Liver lesions ≤ 5 cm with segments II– VI | 14 | 1, 2, 7, 10–12, 14, 16, 20, 21,24–26, 28,29 | 89 (8) | 89 (6) | 67 (11) | 65 (9) | 47 (53) | 49 (55) | 8 |
| Lin et al [ | China | 2008–2012 | PSM (P, S) | Primary CRC and SCRLM | 15–18 | 1–3, 5, 7–16, 20, 21, 24–26, 28 | 7 (0) | 36 (17) | 60 (3) | 57 (10) | 2 (29) | 15 (58) | 8 |
| Jung et al [ | Korea | 2008–2012 | CM (P, S) | Primary CRC and SCRLM | 5, 19 | 1, 2, 7, 9–12, 16, 19– 21, 24, 25, 27, 28 | 24 (25) | 24 (25) | 60 (43–75) | 60 (37–80) | 11 (46) | 7 (29) | 6 |
| Hu et al. [ | China | 2004–2008 | CM (R, M) | Metastasis restricted to the left lobe or a segment in the right lobe with size < 6 cm | 6, 20, 21, 22 | 1, 2, 7, 8, 10, 11, 15, 17–19, 28 | 13 (15) | 13 (15) | 54 (10) | 53 (11) | 3 (23) | 4 (31) | 8 |
| Huh et al [ | Korea | 2003–2008 | CM (P, S) | Primary CRC and SCRLM | NR | 1–3, 5, 7, 9–16, 25, 28 | 20d (NR) | 20 (NR) | 63 (36– 71) | 62 (44–85) | 7 (35) | 5 (25) | 8 |
| Chen et al [ | China | 1999–2005 | CM (R, S) | Rectal tumor fit for Dixon’s surgery and the number of liver lesions ≤ 2 | 21, 23, 24 | 1–10, 13–16 | 23 (26) | 18 (NR) | 55 (10) | 53 (9) | 5 (22) | 4 (22) | 8 |
CRC Colorectal cancer, SCRLM Synchronous liver metastases, CM Case-matched, PSM Propensity score matching, MH Major hepatectomy (≥ 3 segments), P prospectively collected data, R retrospectively collected data, M multicenters, S single center, NR not report
aExclusion criteria are defined as follows: (1) loss to follow-up; (2) with other malignant tumors; (3) combined multiple organ resection;(4) two stage approaches (colorectal first or liver first; (5) combined radiofrequency ablation; (6) extrahepatic metastases; (7) the application of mixed approaches, initially unresectable SCRLM; (8) with hepatic cellular cancer; (9) with neuroendocrine tumor; (10) with benign liver tumor; (11) with peritoneum seeding; (12) mixed approach (laparoscopic colorectal resection and open hepatectomy or vice versa); (13) follow-up< 12 months; (14) tumors close to the portal pedicle or hepatic veins; (15) incomplete material; (16) with obstructive colorectal cancer; (17) with cancer perforation; (18) with T4 colorectal cancer; (19) minor procedures performed by colorectal surgeon only(liver biopsy or wedge resection of synchronous liver metastases in the liver edge); (20) liver metastasis located in the right hemiliver at a size of > 6cm or requiring the resection of > 2 segments; (21) with a previous history of abdominal surgery or tuberculous peritonitis; (22) with serious cardiopulmonary insufficiency; (23)the rectal tumor fit for Mile’s surgery; (24) the number of liver lesions ≥ 3
bMatched factors means the covariate was matched or the difference of the covariate was not statistically significant between two groups and are defined as follows: (1) age; (2) sex; (3) carcinoembryonic antigen; (4) distance between rectal tumors and anus; (5) tumor differentiation; (6) child class; (7) liver metastases size; (8) location of liver metastases (segments 1, 2 ,3, 4b, 4a, 5 ,6, 7, 8); (9) primary tumor size; (10) location of primary tumor (colon/rectum); (11) body mass index; (12) American Society of Anesthesiologists; (13) lymphovascular invasion; (14) depth of primary tumor invasion; (15) postoperative chemotherapy; (16) distribution of metastases (unilobar/bilobar); (17) primary tumor stage; (18) comorbid disease; (19) previous abdomen surgery; (20) types of colorectal and hepatic surgery; (21) number of liver metastases; (22) preoperative chemotherapy; (23) location of liver metastases (anterolateral/posterosuperior); (24) primary tumor T stage; (25) primary nodal status; (26) neoadjuvant chemotherapy; (27) harvested lymph nodes; (28) the type of hepatoenterectomy; (29) recurrence
cThe number (%) of patients > 60 years
dSeven of the 20 patients underwent a total one-step laparoscopic procedure while 13 patients underwent laparoscopic colorectal resection and open liver resection
Clinicopathological characteristics of included studies
| Study | Intervention | Location of primary tumor (colon/rectum) | Primary tumor size, mean | No. of CRLM, mean (SD) | CRLM | CRLM size | R0 rate | Neoadjuvant therapy | Mortality | Conversions |
|---|---|---|---|---|---|---|---|---|---|---|
| Ma et al. [ | Lap | 7/5 | NR | 1.6 (0.9) | 7/5 | 3.73 ± 2.91 | 100/100 | 3 (25) | 0 | 0 |
| Open | 7/5 | NR | 3.1 (1.8) | 5/2 | 3.02 ± 1.62 | 100/100 | 3 (25) | 0 | ||
| Ivanecz et al. [ | Lap | 4/6 | NR | 1.4 (0.9) | 9/1 | 2.0 ± 1.2 | 100/100 | 7 (70) | 0 | 0 |
| Open | 6/4 | NR | 1.4 (0.9) | 9/1 | 2.9 ± 1.5 | 100/100 | 3 (30) | 0 | ||
| Xu et al. [ | Lap | 15/5 | 3.2 (1.0) | 6a | 18/2 | 2.99 ± 1.55 | 100/100 | 6 (30) | 0 | 0 |
| Open | 15/5 | 3.8 (1.2) | 6 | 17/3 | 3.19 ± 1.53 | 100/100 | 4 (20) | 0 | ||
| Chen et al [ | Lap | NR/NR | 4.0 (2.0) | 4a | NR | 5.5 ± 4.2 | NR/NR | NR | 0 | 1 |
| Open | NR/NR | 5.0 (3.0) | 3 | NR | 4.7 ± 3.7 | NR/NR | NR | 0 | ||
| Gorgun et al. [ | Lap | 6/8 | 3.7 (0.7) | 1.6 (0.3) | 12/2 | 2.4 ± 0.7 | 86/NR | 6 (43) | 0 | 0 |
| Open | 14/15 | 3.7 (0.5) | 2.1 ± 0.2 | 19/10 | 2.7 ± 0.2 | 93/NR | 19 (66) | 1 | ||
| Ratti et al [ | Lap | 13/12 | NR | 2.40 ± 1.27 | 13/12 | 3.65 ± 2.67 | 96/100 | 20 (80) | 0 | 1 |
| Open | 27/23 | NR | 2.35 ± 1.34 | 27/23 | 3.94 ± 2.47 | 98/98 | 39 (78) | 0 | ||
| Tranchart et al. [ | Lap | 48/41 | NR | 1.4 ± 0.6 | 78/11 | 2.9 ± 1.9 | 83/NR | 11 (12) | 2 | 6 |
| Open | 51/38 | NR | 1.5 ± 0.7 | 81/8 | 2.8 ± 2.0 | 90/NR | 20 (22) | 0 | ||
| Lin et al [ | Lap | 3/4 | 5.3 (1.1) | 1.9 ± 0.9 | NR | 3.3 ± 1.8 | 100/NR | 3 (27) | 0 | 0 |
| Open | 19/17 | 5.7 (1.9) | 2.1 ± 1.0 | NR | 4.2 ± 2.2 | 100/NR | 13 (36) | 0 | ||
| Jung et al [ | Lap | 18/6 | 5.23 (2.13) | NR | 23/1 | 2.81 ± 1.72 | 100/96 | NR | 0 | 0 |
| Open | 16/8 | 5.56 (1.93) | NR | 18/6 | 3.23 ± 2.21 | 100/100 | NR | 0 | ||
| Hu et al [ | Lap | 8/5 | NR | NR | NR | 3.2 ± 1.0 | NR/NR | 0 (0) | 0 | 0 |
| Open | 8/5 | NR | NR | NR | 3.5 ± 0.9 | NR/NR | 0 (0) | 0 | ||
| Huh et al [ | Lap | 7/13 | 4 (2–10) | 2 (1–7) | 17/3 | 2 (0.9–5.5) | 100/NR | NR | 0 | 0 |
| Open | 11/9 | 4.7 (3–7) | 2 (1–8) | 16/4 | 2.4 (1–10) | 100/NR | NR | 0 | ||
| Chen et al [ | Lap | 0/23 | 2.5 (0.9) | NR | NR | 5.5 ± 1.2 | NR/NR | NR | 0 | 0 |
| Open | 0/18 | 2.3 (1.0) | NR | NR | 5.6 ± 1.4 | NR/NR | NR | 0 |
Lap Laparoscopic surgery, NR Not report
aThe number of patients with CRLM ≥ 3
Secondary outcomes in this meta-analysis
| Outcome of interest | No. of studies | WMD/OR | 95% CIs | ||
|---|---|---|---|---|---|
| Operative time | 12 | 36.57 | 7.80 to 65.35 | 0.013 | 82.4 |
| Blood loss | 12 | − 113.31 | − 189.03 to − 37.59 | 0.003 | 91.4 |
| Hospital stay | 7 | − 2.70 | − 3.99 to − 1.40 | < 0.001 | 53.6 |
| Postoperative stay | 4 | − 3.20 | − 5.06 to − 1.34 | 0.001 | 55.2 |
| 1-year DFS | 4 | 1.05 | 0.59 to 1.86 | 0.86 | 0 |
| 3-year DFS | 4 | 0.66 | 0.41 to 1.08 | 0.097 | 7.5 |
| 1-year OS | 5 | 0.56 | 0.23 to 1.33 | 0.187 | 0 |
| 3-year OS | 6 | 0.94 | 0.53 to 1.65 | 0.822 | 0 |
| 5-year OS | 3 | 0.69 | 0.29 to 1.68 | 0.417 | 0 |
DFS Disease-free survival, OS Overall survival
Fig. 2Meta-analysis for primary outcomes. a Forest plot of meta-analysis in postoperative complications. b Cumulative meta-analysis of postoperative complications
Fig. 3Subgroup analysis based on the types of morbidity